Business
Hugel posts KRW89.8 billion in net sales, marking record Q1 earnings
Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, on May 8 posted KRW89.8 billion, KRW39.0 billion, and KRW30.9 billion for the first quarter net sales, operating profit, and net profit, respectively, based on a consolidated financial statement. With the highest-ever first-quarter earnings for the company, the figures represent increases of 20.9%, 62.6%, and 35.9%, respectively, compared with the same period of 2024.
About this update from Hugel, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"The company logs KRW89.8 billion in net sales, KRW39.0 billion in operating profit, and KRW30.9 billion in net profit, respectively up 20.9%, 62.6%, and 35.9% on-year","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"All product lines such as botulinum toxin, dermal fillers, and cosmetics show steady growth; strong global performance such as additional shipments to the US expected in Q2","length":177,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false},{"type":"text","content":"SEOUL, South Korea, May 8, 2025 /PRNewswire/ -- Hugel Inc., a leading global medical aesthetics company chaired by Suk Cha, on May 8 posted KRW89.8 billion, KRW39.0 billion, and KRW30.9 billion for the first quarter net sales, operating profit, and net profit, respectively, based on a consolidated financial statement. With the highest-ever first-quarter earnings for the company, the figures represent increases of 20.9%, 62.6%, and 35.9%, respectively, compared with the same period of 2024.","length":494,"tagName":"p"},{"type":"image","alt":"Hugel Inc.","displaySize":"","headline":null,"caption":"Hugel Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1280,"height":720,"url":"https://mma.prnewswire.com/media/2682421/HUGEL_Logo.jpg"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y8NfsdfGqXfnxjSzAt97PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://mma.prnewswire.com/media/2682421/HUGEL_Logo.jpg","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kHKN26EC8b2d0QE150_fzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUwO2NmPXdlYnA-/https://mma.prnewswire.com/media/2682421/HUGEL_Logo.jpg","width":1200,"height":675}},"href":"https://mma.prnewswire.com/media/2682421/HUGEL_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The robust earnings growth was driven by balanced gains across all product portfolios.","length":86,"tagName":"p"},{"type":"text","content":"The company's botulinum toxin Botulax, globally branded as Letybo, logged KRW40.7 billion in quarterly net sales, up 18.8% on-year, and made up 45% of the company's total net sales in the January-March period. The toxin's net sales showed the highest growth in the Asia-Pacific market, which includes China, Australia and Taiwan,...